Actively Recruiting
Deciphering Mechanisms Underlying Cancer Immunogenicity
Led by Institut Claudius Regaud · Updated on 2025-09-15
1100
Participants Needed
3
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are studying the expression of PD-1 on T cells in patients with various local or metastatic solid tumors, including head and neck, ovarian, cervical, pre-invasive cervical cancer, glioblastoma, non-small cell lung cancer, and anal cancer. This prospective cohort study involves 1100 patients and aims to better understand immune mechanisms in these cancers. Each tumor type is treated as a separate group for analysis. Participants will receive standard anticancer treatments as part of their usual care. Biological samples including tumor tissue, blood, and ascites (if applicable) will be collected at multiple time points, such as baseline, during surgeries or biopsies, every six months, and at disease progression or recurrence. For those receiving radiotherapy, blood samples will be taken before, at the end, and three months after treatment. The study will follow each patient for up to five years. During the study, patients will undergo sample collections aligned with their clinical care schedule. Researchers will measure the percentage of CD4 and CD8 T cells expressing PD-1 over five years, as well as the presence of tissue resident memory T cells in tumor samples. Participation involves regular monitoring through blood tests and biopsies when clinically indicated, with continued follow-up to observe immune changes related to cancer progression and treatment.
CONDITIONS
Brief Title
Deciphering Mechanisms Underlying Cancer Immunogenicity
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patient with histologically confirmed local or metastatic solid malignant tumor (head and neck, ovarian, cervical, or other types including glioblastoma, NSCLC, anal cancer) or pre-invasive high grade cervical dysplasia (CIN II or III)
- Age 18 years or older at time of study entry
- Patient followed within a standard of care procedure or clinical trial
- ECOG Performance status of 0 to 2
- Able and willing to give informed consent and comply with study protocol
- Affiliated with Social Health Insurance in France
- May participate in other clinical trials
You will not qualify if you...
- Known positive test for Hepatitis B, Hepatitis C, HIV, or Hanta virus
- Any condition preventing blood sampling required by the study (including hemoglobin less than 8 g/dl)
- Pregnant or breastfeeding
- Psychological, familial, geographic, or social situations preventing informed consent or compliance
- Legal or administrative restriction of freedom or under guardianship
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to 5 years from baseline
Participants provide blood samples, tumor biopsy specimens, and ascites samples at various time points including baseline, surgical procedures or tumor biopsies, every 6 months for blood samples, and at disease progression or recurrence. Additional samples are collected for participants undergoing radiotherapy before, at the last session, and 3 months after radiotherapy.
Multiple visits including baseline, surgical procedures, every 6 months, and additional visits at progression or recurrence
Trial Site Locations
Total: 3 locations
1
Hopital Larrey
Toulouse, France, 31059
Actively Recruiting
2
Hopital Rangueil
Toulouse, France, 31059
Actively Recruiting
3
Institut Universitaire du Cancer Toulouse - Oncopole
Toulouse, France
Actively Recruiting
Research Team
A
Alejandra MARTINEZ
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
OTHER
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here